Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohort PrismRA demonstrates a more...

Global TNF Alpha Inhibitors Market Report 2020: Market is Expected to Recover and Reach $42.86 Billion in 2023 - Long-term Forecast to 2025 & 2030 Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "TNF Alpha Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. The global...

Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has...

Global $2.27 Billion Adalimumab, Infliximab and Etanercept Biosimilars Market to 2030 Dublin, Feb. 03, 2021 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to...

Adalimumab Biosimilar Landscape Report Provides an Analysis of 35+ Companies along with Updated 45+ Marketed and Pipeline Drugs | DelveInsight Los Angeles, USA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Adalimumab Biosimilar Landscape Report Provides an Analysis of 35+ Companies along with Updated 45+ Marketed and Pipeline Drugs | DelveInsight  ...